Home › Funds › Goldman Sachs › Goldman Sachs Future Health Care Equity ETF
Fund family: Goldman Sachs · Filed by Goldman Sachs ETF Trust (CIK 1479026) · SEC series S000072296
Ticker: GDOC (C000228400)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 400 with, 8 against, 0 abstentions (not counted as with management); 7 items carried no recommendation. Shareholder proposals: 7 FOR, 8 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Goldman Sachs’s manager page (297,743 ballot items across 86 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Goldman Sachs | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.9% | 373 | 94.3% | 240,212 |
| Backed environmental and social shareholder proposals at US companies | n/a | 4 | 0.0% | 2,372 |
Each ballot item this fund voted is set against the votes of the other Goldman Sachs funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Goldman Sachs funds on all 405 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 73.5% of this fund’s 408 such votes could be given a sector; the other 108 (26.5%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 269 | 8 | 3.0% |
| Industrials | 31 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 255 | 0 |
| Audit-related | 42 | 0 |
| Say-on-Pay | 38 | 0 |
| Compensation | 32 | 0 |
| Corporate Governance | 28 | 4 |
| Capital Structure | 17 | 0 |
| Other Social Issues | 3 | 2 |
| Environment or Climate | 2 | 2 |
| Shareholder Rights and Defenses | 2 | 0 |
| Extraordinary Transactions | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $4M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $2M | 15 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $2M | 18 | 3 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $1M | 13 | 0 |
| Guardant Health, Inc. | June 17, 2026 | $1M | 5 | 0 |
| argenx SE | May 6, 2026 | $1M | 12 | 0 |
| argenx SE | November 18, 2025 | $879,629 | 1 | 0 |
| Intuitive Surgical, Inc. | April 30, 2026 | $876,813 | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
420 ballot items at 44 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Goldman Sachs Future Health Care Equity ETF (GDOC) voted at 44 shareholder meetings of 41 companies, on 420 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 15 shareholder proposals. It voted FOR the board's own proposals more often than Goldman Sachs's funds as a whole (97.9% against 94.3%). It voted the same way as most Goldman Sachs funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Goldman Sachs’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.